FDA restricts Keytruda, Tecentriq monotherapy

FDA restricted the labels of Keytruda pembrolizumab and Tecentriq atezolizumab as monotherapy for urothelial cancer in a first-line setting.

The update applies to

Read the full 226 word article

User Sign In